Abstract
Compounds having the structure of Formula (I): and pharmaceutically acceptable salts thereof, wherein R 1, R 2, R 3, R 4, and R 5 are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent cyclin-dependent kinase 2 (CDK2)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.